Amgen Inc. (NASDAQ: AMGN) Attends Piper Jaffray & Evercore ISI Healthcare Conventions
Amgen Inc. (NASDAQ: AMGN) is a pharmaceutical firm which mainly trusts the “biology first” approach. AMGN uses leading-edge scientific technology to work on tenuous biological procedures so they can cure the diseases of different patients around the world.
Amgen Inc. is attending the Piper Jaffray Conference which is being held in New York city from 27th Nov to 29th Nov 2018. The other conference that Amgen will be present at is the Evercore ISI Healthcare conference, which is being held in Boston. Chief vice president of Global Development at Amgen will be attending the following conventions. This is the 19th annual Healthcare Conference hosted by Piper Jaffray in NYC and over 180 top biotechnology firms will be attending the conference. Mostly including pharmaceuticals, medical technology, drug discovery, and other health care services sectors.
Piper Jaffray Co. was founded in 1895 and is a world known middle-market international investment bank. It fulfills the requirements of middle-market companies. Jon Salveson, head of investment banking at Piper Jaffray stated:
“THIS YEAR’S HEALTH CARE CONFERENCE WILL BE A GREAT OPPORTUNITY FOR INVESTORS TO CONNECT WITH MANAGEMENT FROM NEARLY 300 LEADING PUBLIC AND PRIVATE COMPANIES AND LEARN ABOUT THE FORWARD-GROWTH PROSPECTS THAT WILL BE KEY TO INVESTING STRATEGIES IN THE NEW YEAR.”
Over the period of time, this sort of Health Care Conferences has become an inclusive and well-attended conference in the industry. These conferences are basically held to provide the world with information of different medical and drug companies achievement. So, the participants can ask questions from medical experts and physicians.
Amgen to Expand Use of BLINCYTO After getting Green Signal
Amgen Inc. (NASDAQ: AMGN) has got the green signal from the Committee for Medicinal Products for Human Use (CHMP). The firm will be able to expand their product for the patients with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL). David M. Reese, executive vice president of Research and Development at Amgen said:
“The continued acknowledgment of MRD status as an approvable endpoint is an important step in the larger paradigm shift of ALL management as an early intervention within the ALL treatment continuum has been shown to be an important step in eliminating the dangerous detectable disease. We appreciate the efforts undertaken by the ALL community to work with regulators and other decision makers on the role of MRD in recurrence of disease and look forward to a final decision by the European Commission.”
The biopharmaceutical firm is devoted to what they are doing and enhancing the medical industry with new cures. Amgen Inc. (NASDAQ: AMGN) is focusing on sections which are in need of medical improvement and adds its proficiency to pursue the solutions that will be able to cure diseases and effectively improve patients’ life. Amgen has become one of the biggest biotech firms and has expanded themselves to millions of patients around the globe.